FDA Bets on Biology Over Bureaucracy

FDA's Plausible Mechanism Framework lets gene and RNA therapies win full approval through molecular evidence alone

30 Mar 2026

For most of medical history, a drug had to prove itself against a placebo before regulators would let it near patients. For the rarest genetic conditions, that standard presents an obvious problem: when only a dozen people worldwide share a mutation, a randomised controlled trial is not just difficult. It is impossible.

On February 23rd America's Food and Drug Administration released draft guidance formalising a way around this bind. The "Plausible Mechanism Framework" would allow gene and RNA therapies to gain full regulatory approval based on molecular evidence alone. If a developer can show, with scientific rigour, that a therapy precisely corrects the genetic fault causing a disease and can support that claim with data from untreated patients, that may be enough. Trial size becomes largely irrelevant.

The approach targets genome-editing tools and RNA-based treatments, including antisense oligonucleotides. Among its more practical features is an endorsement of master protocols, which let regulators evaluate therapies targeting multiple mutations within the same gene under a single application. What once required separate filings can now be collapsed into one.

FDA Commissioner Martin Makary announced the guidance at the agency's Rare Disease Day event, saying it would deliver "life-changing therapies to patients at the speed of science." Tracy Beth Høeg of the Centre for Drug Evaluation and Research predicted the framework would "drive increased industry investment in individualized therapies, improving safety and lowering development costs." The scientific rationale for the approach was set out in a paper by Makary and Vinay Prasad published in the New England Journal of Medicine.

Whether the framework lives up to that billing will depend on what follows. Replacing clinical trial evidence with mechanistic inference is a significant departure, and the scientific community's response to the draft, open for public comment until April 27th, will test how broadly that departure is accepted. Mechanistic plausibility is a lower standard than demonstrated efficacy, and regulators have occasionally found the two diverge in uncomfortable ways. The FDA is betting that understanding a disease's molecular cause is proof enough. History suggests it is wise to keep a measure of doubt.